Researchers have shown that brief near-infrared laser exposures lasting 60 seconds can heat retinal pigment epithelium cells to about 44 degrees Celsius, triggering protective heat-shock protein production without causing tissue damage. The preclinical work, conducted in anesthetized pigs and published in Nature Communications, used real-time electroretinography-based temperature monitoring to keep the thermal dose within a narrow safe window. A separate line of evidence has demonstrated that 670 nm light corrects mitochondrial decline in aging retinas, and a registered randomized controlled trial is now testing similar low-level red-light therapy in people with early dry age-related macular degeneration, tracking best-corrected visual acuity and contrast sensitivity as primary endpoints.
Why a 60-second laser pulse could change early AMD treatment
Age-related macular degeneration remains the leading cause of irreversible vision loss in older adults, and the dry form of the disease has no approved therapy that stops progression before the retina suffers permanent structural harm. That gap is what makes the Aalto University-led preclinical study significant: it offers a mechanism for intervening at the cellular level while tissue is still intact. The team applied near-infrared laser exposures lasting 60 seconds to pig retinas and used functional electroretinography signals to estimate temperature in real time, keeping retinal pigment epithelium at roughly 44 degrees Celsius. At that threshold, cells produced heat-shock proteins, molecules that help repair damaged proteins and stabilize cell function, without crossing into destructive thermal territory.
A related but distinct body of research has shown that 670 nm near-infrared light can reverse age-related drops in retinal performance by correcting mitochondrial decline in living tissue. Mitochondria in retinal cells consume more oxygen per gram than almost any other tissue in the body, and their efficiency falls with age. By boosting mitochondrial redox state, 670 nm exposure appears to restore energy supply to photoreceptors before they degenerate. Evidence from animal and human studies indicates that such light can improve mitochondrial function in aging retina, supporting the rationale for clinical trials in early macular disease. The question now is whether combining real-time thermal dosimetry with photobiomodulation in the same early-AMD patient group could produce additive benefits, yielding both a protective heat-shock response and improved mitochondrial output. No published trial has tested that combination, but the biological rationale draws on two converging evidence streams that each target a different stage of cellular stress.
Preclinical and clinical evidence supporting retinal light therapy
The strongest preclinical data come from the Nature Communications study, which solved a practical problem that had stalled earlier attempts at sublethal retinal heating. Previous approaches lacked a reliable way to monitor temperature during treatment, risking either an underdose that failed to activate heat-shock pathways or an overdose that killed cells. The Aalto-led team addressed this by correlating changes in the pig electroretinogram with retinal temperature, creating a feedback loop that held the tissue near the 44-degree Celsius target. Heat-shock protein production confirmed that the hormetic stress response had been triggered, meaning cells mounted a repair program in response to mild thermal challenge.
On the photobiomodulation side, separate studies have tracked what happens when aging retinas receive 670 nm light. Optical monitoring of retinal respiration has shown that this wavelength increases the redox state of mitochondria in vivo, shifting the balance toward more efficient energy production. Clinical translation is already underway. A randomized controlled trial registered as NCT07409389 is evaluating repeated low-level red-light therapy in patients with dry AMD, measuring best-corrected visual acuity via ETDRS letter charts and contrast sensitivity as endpoints. Earlier published trials of photobiomodulation in early and intermediate AMD have reported short-term safety and tolerability data, providing a baseline against which the newer trial’s functional outcomes can be compared.
Taken together, the evidence suggests two distinct but potentially complementary pathways. The thermal approach activates protein-repair machinery through controlled hyperthermia. The 670 nm photobiomodulation approach restores energy metabolism by acting directly on cytochrome c oxidase in the mitochondrial electron transport chain. Both target the retinal pigment epithelium and photoreceptor layer, and both aim to intervene before drusen accumulation and geographic atrophy cause irreversible vision loss.
Gaps between pig retinas and patient outcomes
The most significant unresolved question is whether the hormetic heat response observed in pig retinal pigment epithelium translates reliably to human eyes. Pig and human retinas share anatomical similarities, which is why porcine models are standard in ophthalmic research, but the thermal properties of human RPE, including pigmentation density and choroidal blood flow, differ enough that the 44-degree Celsius window identified in pigs may not map directly. No published human data yet confirm that the same temperature produces the same heat-shock protein cascade without collateral damage.
The registered clinical trial for low-level red-light therapy in dry AMD will generate functional outcome data, but its endpoints, best-corrected visual acuity and contrast sensitivity, do not directly capture the cellular mechanisms that the preclinical work highlights. Even if patients show modest gains in letter scores or contrast thresholds, researchers will still need biomarkers-such as imaging of drusen load, autofluorescence changes in the retinal pigment epithelium, or molecular assays where feasible-to determine whether mitochondrial function and protein-repair pathways are being durably modified. Conversely, a neutral visual outcome would not necessarily falsify the biological rationale, because early-stage structural protection might take longer than a typical trial duration to translate into measurable acuity changes.
There are also safety and dosing uncertainties. The porcine laser experiments used anesthesia and highly controlled fixation, conditions that are not easily replicated in a clinic where patients may move or have variable media opacity from cataract or vitreous changes. Small errors in targeting could concentrate heat in unintended regions, while individual variability in fundus pigmentation could shift the actual temperature achieved for a given laser power. Any first-in-human studies of sublethal retinal heating will therefore need conservative starting parameters, careful dose escalation, and robust monitoring for subtle adverse effects such as microstructural disruption on optical coherence tomography.
For photobiomodulation, the picture is somewhat more mature but still incomplete. Low-level red-light therapy has an established safety profile in other tissues, yet the retina’s extreme metabolic demand and delicate architecture mean that long-term, repeated exposure must be scrutinized. The NCT07409389 trial will help define whether treatment schedules that appear benign over months remain so over years, particularly in older adults who may have comorbid vascular or inflammatory eye conditions. It will also clarify whether any benefits are transient-fading when therapy stops-or whether they persist, implying that mitochondrial reprogramming has occurred.
How future studies could align thermal and photobiomodulation strategies
Designing the next generation of trials will likely require integrating insights from both the thermal and photobiomodulation domains. One possibility is a staged approach in which patients with very early dry AMD receive low-level red-light therapy to bolster mitochondrial resilience, while a subset with specific risk features-such as rapidly enlarging drusen or subtle functional deficits on dark-adaptation testing-are enrolled in carefully monitored studies of sublethal retinal heating. In such protocols, real-time functional feedback analogous to electroretinography-based thermometry in pigs could provide a safety backstop, even if the exact calibration differs in humans.
Another avenue is to develop multimodal imaging and functional testing batteries that can detect small, treatment-induced changes before conventional acuity metrics shift. High-resolution OCT, fundus autofluorescence, microperimetry, and contrast sensitivity under low-luminance conditions could together build a more sensitive picture of how interventions affect retinal health. By correlating these readouts with treatment parameters-wavelength, power, exposure time, and session frequency-researchers may be able to map a therapeutic window that maximizes protective signaling while minimizing any risk of cumulative phototoxicity or thermal injury.
Ultimately, the promise of a 60-second laser pulse or a brief session of red-light exposure is not that they will reverse advanced macular degeneration, but that they might slow or halt the earliest steps in its trajectory. The porcine data show that retinal cells can be nudged into a self-repair mode by precisely controlled heat, while mitochondrial studies suggest that age-dulled energy factories in the eye can be coaxed back toward youthful performance. Whether these laboratory insights will translate into routine clinical tools depends on a sequence of cautious, well-designed human trials that prioritize safety, mechanistic clarity, and long-term follow-up. If that pathway holds, future patients with early dry AMD could face a fundamentally different prognosis-one in which preserving vision is about timely, targeted light rather than waiting for damage and then trying to manage its consequences.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
